ライフサイエンスコーパス: combined therapy

1 conjugated estrogen; r = -0.507, P=0.004 for combined therapy).

2 Lactococcus lactis as tolerogenic adjuvant (combined therapy).

3 blockade, prompting a follow-up trial of the combined therapy.

4 ation, which were further enhanced following combined therapy.

5 treated at some point with either single or combined therapy.

6 d highlights the clinical potential for this combined therapy.

7 moral tissue was still intact 24 h after the combined therapy.

8 im analysis revealed significant benefit for combined therapy.

9 herapy for stable or responding patients was combined therapy.

10 ich PAKs mediate resistance to BRAFi and the combined therapy.

11 hereas there was no effect with IV vitamin C combined therapy.

12 tments further augmented the efficacy of the combined therapy.

13 rlie acquired resistance to BRAFi and to the combined therapy.

14 lease of cargoes to achieve multi-functional combined therapy.

15 utcome was to assess the long-term safety of combined therapy.

16 he realistic application of phage-antibiotic combined therapy.

17 CGT level in tumors subjected to CGT-NP+UTMD combined therapy.

18 otic and autophagy activities induced by the combined therapy.

19 s of contextualization, optimal arousal, and combined therapy.

20 ventricular size and function in response to combined therapy.

21 tion abrogated the therapeutic effect of the combined therapy.

22 nt was eradication of MRD after 12 months of combined therapy.

23 sify therapy, switch to another drug, or use combined therapy.

24 of tamoxifen response and personalisation of combined therapies.

25 tial clinical and immunologic effects of the combined therapies.

26 , it was less common in the groups receiving combined therapy (34/130 [26%]) than in the group treate

27 ng: tracer-determined glucose disposal rate (combined therapy, 52.4 +/- 2.9 mg x kg(-1) x min(-1), vs

28 te grade 3 mucositis was more prevalent with combined therapy, 84% v 43% (P <.001), resulting in a hi

29 lone, as compared with patients who received combined therapy (95 percent confidence interval, 1.10 t

30 In this context, antifungal combined therapy (ACT) has become an emerging strategy a

31 of renal interstitial fibrosis; therefore, a combined therapy aimed at simultaneously targeting multi

32 alysis of pulmonary metastases revealed that combined therapy also had a more potent antimetastatic e

33 Combined therapy also increases tumor destruction over e

34 The combined therapy also reduced tumour weight compared to

35 Combined therapy also resulted in improved local control

36 The combined therapy also synergistically inhibited the accu

37 2.4 +/- 0.4 (standard error of the mean) for combined therapy and 0.9 +/- 0.2 for RF ablation alone (

38 was 49.0 months among patients treated with combined therapy and 29.3 months among those treated wit

39 On other measures the combined therapy and its 2 component therapies produced

40 o significant differences were found between combined therapy and ligation in rebleeding (29% vs. 30%

41 indings highlight an additive benefit of the combined therapy and potential new unique roles of utrop

42 cterize pathophysiological changes following combined therapy and to determine whether radioresponse

43 nal patients (69) were treated with the same combined therapy and were analyzed.

44 increases in the immune responses (from the combined therapy) and duration of antibody response that

45 , 1 patient died suddenly while treated with combined therapy, and 1 patient died of unrelated causes

46 nts had resuscitated cardiac arrest while on combined therapy, and 1 patient had repeated, appropriat

47 i67 proliferation index were documented with combined therapy, and EGFR down-regulation was observed

48 jor treatments were no therapy, monotherapy, combined therapy, and potent antiretroviral therapy, res

49 eing treated with methotrexate-sulfasalazine combined therapy, and two of the patients were being tre

50 beta-blocker therapy and continuous pacing, combined therapy appears to provide reasonable, long-ter

51 e effect of metal ions, and their associated combined therapies, are discussed.

52 rogression-free survival was improved in the combined therapy arm (median not reached) compared with

53 eration, and clonal expansion limited to the combined therapy arm.

54 of disease and intermittent hormone therapy (combined therapy arm; n = 43) or to hormone therapy only

55 Combined therapy, as compared with liposomal doxorubicin

56 ial resistant strains, support the design of combined therapy, as well as assist the development of t

57 Additionally, the combined therapy attenuated the formation of plasminogen

58 This combined therapy attenuates in vivo expression of SPARC,

59 ow that treatment of C57BL/6 donor mice with combined therapy before the transplant protects the reci

60 many cancers, survival depends on aggressive combined therapies, but treatment comes at a price.

61 replicon particles (HPV16-VRP) and that this combined therapy can eradicate human papillomavirus 16 (

62 t demonstrates that orthodontic-regenerative combined therapy can resolve complex clinical problems a

63 Combined therapy caused a predictable fall in hemoglobin

64 noma of the prostate, but outcome using this combined therapy compared with RT alone is not known.

65 duced microvessel counts in the tumors given combined therapy compared with the tumors given either a

66 Furthermore, combined therapies consisting of thermal ablation and ad

67 diopathic long-QT syndrome were treated with combined therapy consisting of continuous cardiac pacing

68 Combined therapy cost $1633 more (P = .01).

69 Therefore, we determined whether combined therapy could normalize insulin action in the Z

70 ptimal dose of anti-CD3 monoclonal antibody (combined therapy [CT], 1 x 5 mug [CT5]) reverts diabetes

71 ptimal dose of anti-CD3 monoclonal antibody (combined therapy [CT], 1 x 5 ug [CT5]) reverts diabetes

72 oup as a whole; however, in 50% of patients, combined therapy decreased PVRI by 20% more than did iNO

73 Surprisingly, the animals treated with the combined therapy did not perform as well as postnatally-

74 deletion of CD20-bearing cells and that the combined therapy did not significantly impair establishe

75 Four patients who received combined therapy died as a direct result of the treatmen

76 The combined therapy diminished bacterial colony-forming uni

77 , 250 microL; total dose, 0.5 mg) alone; (c) combined therapy (doxorubicin injection immediately foll

78 The combined therapy efficiently suppressed T-cell prolifera

79 reduced immunosuppression, whereas a FOLFIRI combined therapy enhanced immunosuppression.

80 The combined therapy enhanced these independent effects of e

81 Combined therapy facilitated T:B cooperativity and enabl

82 d dose (480 mg/m(2)), five patients received combined therapy first and carboplatin alone second, and

83 After receiving a combined therapy for 24 weeks, 43.66% patients showed an

84 yostatin-1 and rituximab could be a valuable combined therapy for B cell malignancies.

85 The necessity to find a combined therapy for both motor and cognitive deficits i

86 ssion and provide an insight for designing a combined therapy for cancer treatment.

87 gest that Bryo-1 plus IL-2 may be a valuable combined therapy for cancer treatment.

88 , and topical growth factors, referred to as combined therapy, for treating hypertrophic scars compar

89 eaths from non-small-cell lung cancer in the combined therapy group (62 vs 31 deaths; 0.09%vs 0.05%;

90 ity (BCVA) improved from 0.73 to 0.53 in the combined therapy group (P < .001) and from 0.79 to 0.72

91 istically significant after 21 months in the combined therapy group and 15 months in the monotherapy

92 mothermia (p < 0.01) (although >40mmHg); the combined therapy group required more fluid boluses (p <

93 achment, whose TNFalpha concentration in the combined therapy group was the lowest value found (53.50

94 h the control group was only achieved in the combined therapy group.

95 the radiotherapy group and 77 percent in the combined-therapy group (P<0.001).

96 te of overall survival was 55 percent in the combined-therapy group and 34 percent in the hyperfracti

97 years were 67 percent among patients in the combined-therapy group and 40 percent among patients in

98 The median survival was 72.2 months in the combined-therapy group and 59.3 months in the monotherap

99 e occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-pla

100 l (P=0.008) were significantly higher in the combined-therapy group at four years.

101 ciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, a

102 akness and dizziness were more common in the combined-therapy group than in the dual-placebo group, b

103 onal control was significantly higher in the combined-therapy group than in the group given radiother

104 ree survival was significantly longer in the combined-therapy group than in the radiotherapy group (h

105 In the combined-therapy group there were higher frequencies of

106 Those in the combined-therapy group who frequently recorded their foo

107 eiving radiotherapy plus short-term ADT (the combined-therapy group), as compared with 57% among pati

108 l and regional control was 82 percent in the combined-therapy group, as compared with 72 percent in t

109 ation for groups 1, 2, and 3 but not for the combined-therapy group.

110 uency of diarrhea and hepatic effects in the combined-therapy group.

111 or the second intracavitary procedure in the combined-therapy group.

112 ate of reversible hematologic effects in the combined-therapy group.

113 the machine-perfusion group, and 479 in the combined-therapy group.

114 acute toxic effects also were greater in the combined therapy groups.

115 ere generally similar in the monotherapy and combined therapy groups.

116 ized freeze-dried bone (DFDB) grafting (BG), combined therapy (GTR + BG) and a DFDB-glycoprotein spon

117 However, for non-contained defects, combined therapy (GTR + BG) demonstrated clinically sign

118 96 women assigned to combined therapy had non-small-cell lung cancer compared

119 Use of combined therapy has been proposed, using a bone graft i

120 The value of combined therapy has not been clearly established.

121 This fully oral, chemotherapy-free, triplet combined therapy has the potential to be an alternative

122 Combined therapy, however, demonstrated both favorable e

123 Resistance to the combined therapy, however, is mediated by mechanisms ind

124 MS-275 and liraglutide combined therapy improved fasting glycemia upon short-te

125 s lesions, supporting the potential of these combined therapies in the treatment of advanced atherosc

126 out toxicity, showing the potential of these combined therapies in the treatment of advanced atherosc

127 rt demonstrates orthodontic and regenerative combined therapy in a 49-year-old male whose right maxil

128 Furthermore, combined therapy in mice markedly decreased the growth o

129 podia regulation that points to the need for combined therapy in order to prevent invadopodia-mediate

130 s to summarize our long-term experience with combined therapy in patients with long-QT syndrome.

131 These studies indicate a possible role for combined therapy in the treatment of GLD.

132 possibility that both agents can be used as combined therapy in the treatment of ischemic heart dise

133 and decreased during both lisinopril and the combined therapy in which it was not different from base

134 The combined therapy increased perfusion, motor function, an

135 Combined therapy increases the survival of patients who

136 In comparison with individual treatments, combined therapy (iNO + dipyridamole) did not augment pu

137 These data suggest that combined therapy is a promising strategy for prevention

138 utic responses are T-cell-dependent, because combined therapy is not efficacious in severe combined i

139 observed in DMD patients, the effect of the combined therapy is slightly attenuated but still benefi

140 t of the widespread clinical impression that combined therapy is superior to psychotherapy alone for

141 al role played by PRP, BPBM, and GTR in this combined therapy is unclear and needs to be elucidated.

142 Further study of this form of combined therapy is warranted.

143 In experiment 2, use of combined therapy led to increased coagulation in all tis

144 Combined therapy lengthens the time required for treatme

145 At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, w

146 at 84 weeks and 2 participants receiving all combined therapies maintained viral loads below 1000 cop

147 ng on a decision maker's willingness to pay, combined therapy may be cost-effective, particularly for

148 effects of AAVs carrying NGF versus BDNF, a combined therapy may be ideal for PN.

149 effective only as long as they are used, and combined therapy may be more effective than monotherapy.

150 This study suggests that this triple-combined therapy may benefit a subset of patients with B

151 Combined therapy may improve outcome relative to monothe

152 and glucocorticoids plus rituximab were the combined therapies most frequently employed during remis

153 injected liposomal doxorubicin (n = 26), or combined therapy (n = 30) and were compared with control

154 solated bileaflet chordal cutting versus the combined therapy (n=7 each).

155 therapy plus antidepressant pharmacotherapy (combined therapy; n = 352).

156 Therefore, combined therapies of anti-CD154 antibodies plus donor-s

157 tudy, we present seven patients for whom the combined therapies of PP/IVIG were successful in reversi

158 pes or pulsed-HIFU exposure in addition to a combined therapy of (90)Y-B3 and taxol to enhance the sy

159 Combined therapy of alphabeta-TCR-CsA for 7 days resulte

160 s stages of prostate cancer cells and that a combined therapy of antiandrogens and anti-PI3K/Akt inhi

161 e increased to 5.98 (95% CI, 0.72-216.0) for combined therapy of atorvastatin, pravastatin, or simvas

162 A combined therapy of avasimibe plus an anti-PD-1 antibody

163 These effects are rescued with the combined therapy of blocking GABA(B)Rs and NMDARs, indic

164 est that MiPs should be further explored for combined therapy of cardiac and skeletal muscles.

165 Clinically, combined therapy of cisplatin (CDDP) and metformin is an

166 Combined therapy of cisplatin and ATP11B-targeted siRNA

167 findings suggest consideration of applying a combined therapy of GLS inhibitor and PARP inhibitor to

168 rpose of this study was to determine whether combined therapy of glutaraldehyde-polymerized bovine he

169 The combined therapy of NB-UV-B and afamelanotide appears to

170 Women who used a combined therapy of oestrogen with cyclic progestagen (e

171 Postmenopausal women who use combined therapy of oestrogen with cyclic progestagen on

172 mm +/- 0.9 (P: <.001) was observed with the combined therapy of PEI followed by RF.

173 icroL of ethanol infused over 1 minute); (c) combined therapy of PEI immediately followed by RF ablat

174 The combined therapy of PRO and PD-(L)1 inhibitor decreased

175 immediately followed by RF ablation; or (d) combined therapy of RF ablation immediately followed by

176 Moreover, combined therapy of RSpo1 and keratinocyte growth factor

177 BMP7 and LfcinB as individual treatments and combined therapy on bovine nucleus pulposus (NP) cells b

178 n are added to statin therapy, the effect of combined therapy on LDL cholesterol levels is additive.

179 The effect of combined therapy on PAI-1 [5.6 (2.3, 8.8) ng/mL] was sig

180 dothelium, leading to synergistic effects of combined therapy on tissue perfusion.

181 d for selecting patients for more aggressive combined therapies or enrollment into trials targeting E

182 engineered into multispecific constructs for combined therapies or for use in new strategies such as

183 These findings do not support the use of combined therapy or of extended treatment duration.

184 of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-m

185 s was 5 degrees C lower for tumors receiving combined therapy (P < 0.01).

186 he first antimicrobial used or lowest MIC of combined therapy (P = 0.006).

187 change in PAI-1 during ramipril (P=0.011) or combined therapy (P=0.006) but not during estrogens (P=0

188 In cells that are resistant to the combined therapy, PAKs regulate JNK and beta-catenin pho

189 In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 1

190 Model-predicted cellular responses to the combined therapy provide good agreement with experimenta

191 Finally, combined therapy provoked brisk infiltration and intratu

192 A FOLFOX combined therapy reduced immunosuppression, whereas a FO

193 This combined therapy reduces airway inflammation, remodeling

194 and abandonment of treatment modalities and combined therapy regimens were examined overall, by coun

195 Furthermore, nintedanib and bufalin combined therapy relieved the tumor microenvironment and

196 Combined therapy required significantly more sessions to

197 Moreover, the CD4(+)/SOCS1-KIR combined therapy resulted in decreased leukocytic organ

198 In the subcutaneous tumor model, the combined therapy resulted in improved survival.

199 Combined therapy resulted in significantly longer period

200 Combined therapy results in modest 12-month improvement

201 We show that this combined therapy reversed NASH and reduced NASH-driven H

202 five patients received carboplatin first and combined therapy second.

203 The combined therapy significantly improved antitumor activi

204 Combined therapy significantly increased overall surviva

205 Our analysis showed that the combined therapy significantly outperformed monotherapy

206 This combined therapy significantly prolonged the life span o

207 but the response to iNO was not augmented by combined therapy (SOD + iNO).

208 As a consequence of this combined therapy, strains resistant only to rifampin wer

209 Finally, a triple-response combined therapy strategy is achieved by PEGylated BP na

210 ttempted, but the effects of augmentation on combined therapies, such as cognitive remediation and so

211 as paved the way to consider refinements and combined therapies, such as the use of biomaterials to a

212 mouse model of autoimmune diabetes, we show combined therapy supports regulatory T cell homeostasis

213 Moreover, our combined therapy synergistically attenuates tumor growth

214 phages manifested an M2-like profile(3), the combined therapy synergistically enhanced antitumour eff

215 rotection during ALI opens possibilities for combined therapies targeted to this protein set.

216 Combined therapies targeting aberrant properties of LSC

217 Combined therapies targeting common and subtype-specific

218 neuroprotective activities, suggesting that combined therapies targeting distinct Ass42 epitopes can

219 Combined therapies targeting glucose metabolism and poly

220 nhibitors, by targeted ER degradation, or by combined therapy targeting both ER and growth factor sig

221 pport a personalized medicine approach where combined therapy targeting YAP and Bcl-2, tailored to NF

222 ic blood pressure was 6.2 mm Hg greater with combined therapy than with dual placebo.

223 te of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.

224 dentify new therapeutic targets, and lead to combined therapies that are effective against highly het

225 ical evidence-based adjunctive therapies and combined therapies that can be used to tailor individual

226 oenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the bi

227 as well as serve as a critical component in combined therapies to target and eliminate CSCs.

228 lenge current trial design paradigm that for combined therapy to be successful individual agents shou

229 The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be

230 ing the framework for clinical evaluation of combined therapy to improve patient outcome in MM.

231 s to lie in a multidimensional approach with combined therapy to manage both cancer cachexia and asth

232 preclinical data supporting the use of this combined therapy to overcome the limitations of standard

233 ify LDLR as a promising metabolic target for combined therapy, to limit PDAC progression and disease

234 (51.5%), 21 biologic trials (32.8%), and 10 combined therapy trials (15.6%).

235 t different sites and may help us to develop combined therapies using anti-AR and anti-VEGF-C compoun

236 rogramming CAFs and provides a rationale for combined therapies using inhibitors of AKT and CX3CR1.

237 Combined therapy using both sorafenib and MEAN enhanced

238 Our findings reveal the potential for combined therapy using optimized doses of Physcion and D

239 85% of patients (39 of 46) in group A given combined therapy versus 11% (5 of 46) receiving lamivudi

240 rred in 31% of patients (14 of 45) receiving combined therapy versus 6% (3 of 48) receiving lamivudin

241 No advantages were observed with combined therapy versus benznidazole monotherapy.

242 widths were also significantly greater with combined therapy versus PF alone (8.6+/-1.8 mm radiofreq

243 (10% had life-threatening toxic effects with combined therapy vs 2% in the RT only group).

244 years of follow-up the overall survival for combined therapy was 26% (95% confidence interval [CI],

245 The 6-month maintenance response rate for combined therapy was 57.1% for the PDSS (P=.04 vs CBT al

246 Combined therapy was administered for 24 cycles.

247 In the randomized study, combined therapy was compared with RT only (n = 62): 64

248 Combined therapy was estimated to result in meaningful g

249 A and SAMe treatment prevented this fall and combined therapy was more effective on preserving GSH le

250 Combined therapy was more likely to produce clinically s

251 This combined therapy was not lymphocyte depleting and did no

252 Whereas combined therapy was not significantly more effective th

253 Subgroup analysis revealed that combined therapy was notably more effective in reducing

254 Twelve combined therapies were conducted in the 11 patients.

255 s (56 underwent monotherapy and 72 underwent combined therapy), which were followed-up for up to 15 m

256 dge, and argue that significant progress for combined therapies will require a better understanding o

257 roaches as well as their potential to obtain combined therapies with desired drug release profiles.

258 b, adalimumab, certolizumab, vedolizumab, or combined therapies with placebo or an active agent for i

259 2139 once per week for 15 weeks, followed by combined therapy with 250 mg intravenous REP 2139 and 18

260 In contrast, combined therapy with a cytotoxic agent and anti-PDL1 bl

261 Additionally, combined therapy with a FAK inhibitor and the antiangiog

262 d acute myeloid leukaemia and were receiving combined therapy with a FLT3 inhibitor.

263 Combined therapy with abciximab and ticlopidine has a pr

264 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA en

265 ffectively improve the treatment efficacy of combined therapy with ADT and vaccination.

266 We recommend combined therapy with albendazole and prednisolone, with

267 ment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has b

268 Combined therapy with anti-BRAF plus anti-MEK is current

269 Combined therapy with antibiotics and antirejection medi

270 We demonstrate that combined therapy with antigen-induced CD4 derived DN Tre

271 nscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody specific to

272 Additionally, the impact of combined therapy with aspirin and other COX inhibitors i

273 Importantly, combined therapy with bortezomib plus cisplatin induced

274 Combined therapy with both Src and PI3K/PKB inhibitors m

275 l hemodynamic response to traditional NSBBs, combined therapy with carvedilol plus simvastatin signif

276 Although combined therapy with cyclophosphamide and glucocorticoi

277 Combined therapy with dabrafenib plus trametinib was app

278 Initial results indicate that combined therapy with etanercept plus methotrexate may b

279 Here we demonstrate that combined therapy with human GM-CSF and low-dose IL-2 is

280 tained with the combination, suggesting that combined therapy with IGF-1 and OP-1 may be an effective

281 vidence in this study strongly suggests that combined therapy with inhibitors of YAP (such as vertepo

282 o treatment demonstrates a possible role for combined therapy with iNO and PGI2 in infants with sever

283 c intermediates, we assessed the efficacy of combined therapy with lovastatin and cholesterol.

284 PTEN/PI3K pathway that would be amenable to combined therapy with MAPK pathway inhibitors for the tr

285 These results suggest that combined therapy with NSAIDs and antioxidants might be u

286 l was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or

287 Therefore, we evaluated whether combined therapy with paclitaxel and LY294002 would resu

288 patients with C4d positive AHR who received combined therapy with PPH and polyclonal rabbit antithym

289 b treatment that subsequently resolved after combined therapy with rituximab and daratumumab.

290 ctivator (rtPA) makes it a candidate for the combined therapy with rtPA for the acute treatment of is

291 imus (3 mg/kg per day for 14 days); group 4, combined therapy with sirolimus and mCTLA-4Ig.

292 Combined therapy with these two agents very effectively

293 Combined therapy with thrombospondin-1 type I repeats (3

294 Interestingly, the combined therapy with vamifeport and the erythroid matur

295 Combined therapy with warfarin and aspirin has been show

296 e compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihype

297 Combined therapy yielded significantly greater lengths o